Promomed

Promomed is a Russian pharmaceutical company engaged in the development, production, research and distribution of medicines. The company's main production site is the Biochemik plant in Saransk.
P/E
Net profit
P/B
Book value
P/FCF
FCF
Yield
Growth potential

Promomed balance sheet

Report period2019 2020 2021 2022 2023 Q2 24
End date of the reporting period
Capitalization, ₽
Capitalization, $
Enterprise Value
Book Value
Shareholders Book Value
Current liabilities
Noncurrent liabilities
Total liabilities
Debt
Cash and cash equivalents
Net debt
Assets
Total ordinary shares
Ordinary share price

Promomed cash flows

Report period2019 2020 2021 2022 2023 Q2 24 TTM
End date of the reporting period
Sales
Gross profit
Operation Income
Earnings
Shareholders earnings
EBITDA
Adjusted EBITDA
Operation Cashflow
Capital expenditure
Free Cash Flow
EPS

Promomed multipliers

Report period2019 2020 2021 2022 2023 Q2 24 TTM
P/E
E/P
P/B
P/S
P/FCF
L/A
Debt-To-Equity
Net Debt/EBITDA
EV/EBITDA

Promomed profitability

Report period2019 2020 2021 2022 2023 Q2 24 TTM
ROA
ROE
ROS
Gross margin
EBITDA Margin
Operating margin
Promomed assets
Promomed cash flows

Promomed dividend policy

The amount of dividends is determined based on the following ratio: Net Debt / Adj. EBITDA ≤ 1 - at least 50% of Adj. earnings; 1 < Net Debt / Adj. EBITDA ≤ 2 - at least 25% of Adj. earnings; 2 < Net Debt / Adj. EBITDA ≤ 2.5 - at least 15% of Adj. earnings. The basis for calculation is IFRS reporting.
Promomed operating results
by year
Number of periods: 1
Report period2024
Evolution index basic portfolio, percentage points
Evolution index endocrinology portfolio, percentage points
Index of evolution of oncology portfolio, percentage points
Own trademarks, things

Promomed shares

TickerNameTypeNominal valueISINPrice
PRMD:RMPromomedCommon shareRUB 1RU000A108JF7RUB 406.3

Promomed bonds

NameIssue sizePriceYield
PROMOMED DM 002P-01 (RUB)3,500,000 pcs.91.62%19.58%
PROMOMED DM 001P-03 (RUB)2,500,000 pcs.100%8.84%
PROMOMED DM 001P-01 (RUB)1,000,000 pcs.100.02%0.06%
PROMOMED DM 001P-02 (RUB)977,896 pcs.99.96%0.03%

Promomed expected events

DateTypeNoteSource
23.04.2025 10:00
Financial results
Reporting for 2024 under IFRSPictogram of promomed.ru  promomed.ru
20.05.2025 10:00
Operating results
Operating results for 3 months of 2025Pictogram of promomed.ru  promomed.ru
12.08.2025 10:00
Operating results
Operating results for 6 months of 2025Pictogram of promomed.ru  promomed.ru
28.08.2025 10:00
Financial results
Reporting for 1H 2025 under IFRSIPictogram of promomed.ru  promomed.ru
28.08.2025 10:00
Financial results
Financial statements for 6 months of 2025 under IFRSPictogram of promomed.ru  promomed.ru
18.11.2025 10:00
Operating results
Operating results for 9 months of 2025Pictogram of promomed.ru  promomed.ru
Share capital structure of Promomed
Promomed news
29.03.2025
Promomed's RAS loss for 2024 amounted to ₽69.38 million, down 31.2% from ₽100.8 million in the previous year.
Source: {source} pictogram e-disclosure.ru
Pictogram next
20.02.2025
Promomed Group expects demand for its overweight and obesity drug to grow tenfold this year. The company introduced Velgia in early October 2024, and by the end of the year sales had already reached ₽1 billion.
Source: {source} pictogram ria.ru
Pictogram next
20.02.2025
Promomed's revenue for 2024 amounted to ₽21.1 billion, up 33% year-on-year. Share of revenue from sales of innovative products increased by 10 p.p. to 58%. Volume of export sales increased by 46%.
Source: {source} pictogram promomed.ru
Pictogram next
13.02.2025
Promomed's sales in January 2025 increased by 28% year-on-year. Share of revenue from sales of innovative products reached 70%, which is 26 p.p. higher than a year earlier. Notable contribution to the increase in sales was made by the launch of the innovative drug Velgia®, which accounted for 42% of sales in the Endocrinology segment. Shipments of such produ...
Source: {source} pictogram promomed.ru
Pictogram next
All Promomed news
General information
Company namePromomed
Tags#biotechnology, #pharmacy, #ipo2024
SectorHealth Care / Pharmaceuticals, Biotechnology & Life Sciences / Biotechnology / Biotechnology
Business addressMoskva, prospekt Mira, dom 13, stroenie 1
Mailing address129090, g. Moskva, prospekt Mira, dom 13, stroenie 1, etazh 2, pomeschenie 5
Websitepromomed.ru
Information disclosuree-disclosure.ru